Navigation Links
Mental Illness Reversed with Anti-retrovirals in HIV Cases

Amazing new research has revealed that anti-retrovirals (ARVs) in HIV infected people can reverse mental illness. HIV-infection has been known to cause mental illness// through the central nervous system, with about 40% of Aids sufferers having major depression in South Africa.

Dr Michelle Rogers, a psychiatrist, says: "There were several really dramatic findings. I think the most notable of those is the incredible response that patients have to ARVs in the advanced stages of HIV when they have mental illness."

However there is a lack of such research in SA as well as in other developing countries. Aids treatment initiatives has yet to include mental healthcare.

Dr Soraya Seedat from the Stellenbosch University, says: "It has changed the way in which we address treatment and I think psychiatrists have become even more aware of issues of informed consent, voluntary counselling, and testing in his population, particularly because they are vulnerable and their psychological state is already compromised."

According to the South African Society of Psychiatrists HIV is changing the face of psychiatry but even in this year's International Aids Conference, the mentally ill living with HIV/Aids was not high up on the agenda. However this is soon expected to change with their growing numbers soon demanding the attention of government and Aids activist groups.
NLA
'"/>




Page: 1

Related medicine news :

1. Mental illness a key factor in suicide
2. Mental retardation linked to brain protein
3. Mental growth in babies at risk
4. Reduced Fatigue Boosts Mental Health
5. Mental Health Services for Children
6. Mentally Demanding Jobs Found To Reduce The Risk Of Alzheimer’
7. Diabetics To Seek Mental Counseling To Cope With Stress
8. Exercise Can Decrease Mental Decline
9. Low Socioeconomic Status May Lead To Mental Illness
10. Mental health may deteriorate as early as in the teens
11. Folic Acid Retards Mental Decline In Middle Aged Subjects

Post Your Comments:
(Date:11/7/2009)...HOUSTON, Nov. 7 The Ame...Lisa James, Director of Health at the Family Viole...uished Service today at its semi-annual policy-mak...ce is the highest honor the AMA House of Delegates...p://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ...
(Date:11/7/2009)...HOUSTON, Nov. 7 Calling this a "de...n (AMA), the AMA President J. James Rohack, M.D., ...ians from all state and medical specialty societie...aking meeting, where health system reform will top.../cgi-bin/prnh/20081209/AMALOGO ) ,, "Over the...
(Date:11/7/2009)...WASHINGTON, Nov. 7 With..., antichoice extremists are holding the entire bil...ey are demanding that the bill go far beyond the s...ncorporated into the original bill. In an outrage...rly Saturday afternoon, antichoice Democrats are d...
(Date:11/7/2009)...WASHINGTON, Nov. 7 The ... of Representatives to vote for the Stupak-Ellswor... Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski...l law on abortion funding and conscience protectio...H.R. 3962)," they said. ,, The letter was signe...
(Date:11/7/2009)...GTON, Nov. 7 Americans United for Life Action end...tupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-S...al money from going to abortion in health care ref...nt and CEO Dr. Charmaine Yoest said, "Americans Un...Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith A...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2
...The Procter & Gamble,Company (NYSE: PG ) ann...61,percent increase for the October - December qua...m the Folgers transaction completed during the,qua...es were three percent below the year-ago quarter a...
...wo-thirds of Americans classified by the governmen...rent economic environment making it even more diff...ed Dr. Olga Stevko, Clinical Hypnotherapist and MD...individual and group sessions. Dr. Olga and her pr...
...nt and Future Growth Opportunities in Transplant D...an Expansion Strategy - , , SAN DIEGO, Calif., Ja... pioneer and leader in nucleic acid diagnostics fo... rapidly growing molecular diagnostics company bas...
...or, rapid transport, and,artificial blood products...,soldiers during the wars in Iraq and Afghanistan....cal transit from battlefield to combat hospitals i...),could be a viable new option for physicians trea...
...ominate State Fiscal Landscape, AHCA/Alliance Urge...deral Medicaid Funds , , WASHINGTON, Jan. 29 W... for vulnerable populations increasing at an alarm...er that will better protect U.S. seniors, ongoing ...
... Varian Medical,Systems (NYSE: VAR ) today repor...56 per diluted share in the first quarter of fisca...erations of $0.46 per diluted share in the year-ag...,continuing operations in the year-ago quarter, fi...
Other Medicine News:Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 2Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 3Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 4Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 5Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 6Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 7Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 8Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 9Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 10Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 11Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 12Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 13Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 14Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 15Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 16Health News:P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations 17Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 3Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 2Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 3Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 4Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 5Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 6Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 7Health News:Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash 8Health News:Regional Anesthesia Eases Wounded Soldiers' Pain in Iraq and Afghanistan 2Health News:Regional Anesthesia Eases Wounded Soldiers' Pain in Iraq and Afghanistan 3Health News:Stimulus Bill Requires Modification in U.S. Senate to Better Protect Seniors' Ongoing Access to Quality Nursing Home Care 2Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2009 7
(Date:11/5/2009)...lthea Technologies, Inc., a leading provider of de...ceutical products announced the addition of custom...form of services, which will be overseen by the ne...ulation Development. This investment in an experie..., along with new laboratory facilities and state-o...
(Date:11/5/2009)...FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HB...II trial of Topical Interferon Alpha-2b for the tr...atient enrollment, with the required 120th patient...lind and placebo-controlled Phase II trial is unde...atients participating in the trial self-administer...
(Date:11/5/2009)...e/ -- Renee Cobos, MD, a board certified dermatolo... University of California, Irvine, announced today...ults with Thermage CPT®. The updated system, ...ng, features a new vibrating hand piece that incre...rt. ,, "Thermage has always been popular with ...
Breaking Medicine Technology:Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 1Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 3Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 4The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 1The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 2The San Francisco SPCA Launches Online Guide for Summer Pet Health 26 Safety 53233 3Governor Eliminates Funding to Domestic Violence Programs 53230 1Governor Eliminates Funding to Domestic Violence Programs 53230 2
...rimary Endpoint for Clinical,Trials; Data Presente...ongress -, SOUTH PLAINFIELD, N.J., Sept. 30 PTC ... findings in patients with Duchenne/Becker,Muscula...rld Muscle Society,(WMS) Congress. Results from an...6-minute walk test (6MWT) as a primary outcome mea...
... AMD patients, LOUISVILLE, Ky., Sept. 29 Potenti...company developing medicines for the treatment,of ...oday that the,Company,s leading drug candidate, PO...s Phase I study. POT-4 is a complement inhibitor, ... that could otherwise lead to local,inflammation, ...
Other Medicine Technology:PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 5Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2
Cypher Stent
PT2LS Guide Wire (light support)
Fort Floppy
Lieberman Wire Angled Speculum
Medicine Products: